Dr. Daniel Feig, MD, PhD

Dr. Feig practices at University of Alabama Birmingham Hospital in Birmingham, Alabama.

Dr. Feig's NPI, 1942380290, was assigned on October 17, 2006. Dr. Feig graduated from University Of Washington School Of Medicine in 1995. Dr. Feig's Alabama license number on file is 30825.

Dr. Feig's primary practice is University of Alabama Birmingham Hospital, at 619 19th S St, Birmingham, AL 35211 in Jefferson County. The practice phone is (205) 731-9770.

Dr. Feig's primary practice is University of Alabama Birmingham Hospital in Birmingham, Alabama. Dr. Feig is also affiliated with UAB Hospital. The medical group on file is UAB Medicine. Dmand AI also links Dr. Feig to 1 more hospital and 1 dialysis center, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Feig practices, 3 sites in all. Vendor and product names are available with a free account.

Pediatric nephrology is Dr. Feig's primary specialty in the NPI Registry, under taxonomy code 2080P0210X. Dr. Feig is board certified in pediatric nephrology by the American Board of Pediatrics. Dmand AI has Dr. Feig's licenses on file in 3 states: Alabama, Texas and Washington.

CMS data shows 39 Medicare services from Dr. Feig across 1 procedure code in 2024, all of them office visits, for 36 Medicare patients. Medicare paid $2,295 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 36 Medicare patients who saw Dr. Feig in 2024. The largest group is under 65, with 36 patients. 75% of them have chronic kidney disease, and 72% have high blood pressure. Their average risk score is 6.39, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Feig's median patient age at 15, with 35% women.

In 2024, Dr. Feig wrote 227 Medicare Part D claims for 20 patients. 75% of them were for generic drugs. CMS names the drug for 94 of them, across 6 drugs with 11 or more claims each, at $44,760 in total drug cost. In 2023, CMS named 97 claims across 7 drugs.

Dr. Feig accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 94 papers to Dr. Feig, published from 2003 to 2025. 2016 was the busiest year, with 7. The most frequent topics are Uric Acid, Hypertension and Hyperuricemia. Dr. Feig has published most often in Pediatr Nephrol. Dr. Feig's most frequent co-authors are Richard J. Johnson, MD, Mark S. Segal, MD and Michael Edward Seifert, MD.

Dmand AI links Dr. Feig to 4 clinical trials, 3 of them phase 2 studies. Conditions studied include Hypertension, Essential Hypertension and Nephrotic Syndrome. National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) sponsors the most, 2.

CMS Open Payments shows 35 general payments to Dr. Feig from 17 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 89% of the total. Alnylam Pharmaceuticals Inc. paid the most, $5,173.

Dmand AI lists 3 awards for Dr. Feig, most recently Regional Top Doctor in 2014.

Dr. Feig graduated from University Of Washington School Of Medicine in 1995. Dr. Feig is a member of AAP.

Dr. Feig is in network with 12 carriers, including Aetna, Elevance and United Healthcare. Medicare plans come from the most carriers, 8. Check the plan with the practice before a visit.